Abstract
Introduction

CD4
+
CD25
+ regulatory T cells (Tregs) serve an important suppressive function, limiting potentially pathogenic immune responses to self-and foreign antigens (1, 2). Their ex vivo manipulation and reintroduction is likely to become an important immunotherapy in clinical practice (3, 4), necessitating an understanding of the factors required to maintain the regulatory phenotype in vitro.
Since the identification of the IL-2R a chain (CD25) as a marker for this regulatory population (5), the role of IL-2 in their normal homeostasis and function has become increasingly clear (6). Mice genetically engineered to be deficient in lymphocyte IL-2 signaling develop lethal autoimmune disease (7-10), attributed to a failure in Treg development (11). Subsequent work has revealed that transfer of CD4
Tregs from wild-type mice prevents disease in this model and that restoration of IL-2 signaling in CD4 + T cells allows the normal development of . This work has been confirmed by the treatment of normal mice with anti-IL-2 antibodies, which deplete CD4 + CD25 + Tregs (16) and induce autoimmune disease (17) in a similar fashion to the genetic studies. IL-2 is also a survival factor that limits the apoptosis of Tregs in vitro (18) and-together with TCR stimulation-has been implicated in the suppressive activity of murine CD4 CD25 is a unique component of the high-affinity IL-2R, which also includes a b chain (CD122)-shared by the IL-15R-and a common gamma chain (c c ) (CD132)-shared by the receptors for IL-4, IL-7, IL-9, IL-15 and IL-21. The cytoplasmic domains of the b and c chains are responsible for signaling, which occurs by the recruitment and activation of Janus-activated kinases 1 and 3, with activation of both the signal transducer and activator of transcription (STAT) factor 5 and the dual phosphatidylinositol 3-kinase (PI3K) and Ras mitogen-activated protein kinase pathways (24, 25). The shared receptor components allow elements of IL-2 signaling to be induced by the other c c cytokines, though IL-4 stands out as being a somewhat unique member of this family (24, 26). For example, with the exception of IL-4, all the c c cytokines activate STAT5 (24). Furthermore, IL-2, IL-7 and IL-15 regulate virtually identical sets of genes in T cells, whereas IL-4 induces only a partially overlapping-and largely distinct-profile of genes (27) .
The role of cytokines other than IL-2 in CD4 + CD25 + Treg homeostasis and activation is being increasingly recognized. Although reduced in number, CD4
+ CD25 + Foxp3
+ cells are nevertheless present in IL-2 À/À mice (28), and at higher frequency than in STAT5 À/À mice (29); similarly, a human patient with a mis-sense A630P STAT5b mutation showed decreased numbers, forkhead box protein 3, human nomenclature (FOXP3) expression and suppressor function of CD4 + CD25 HI Tregs (30) . Moreover, constitutive activation of STAT5 within lymphocytes results in an expanded population of highly potent CD4 + CD25 + Tregs, suggesting that cytokines other than IL-2 able to activate STAT5 may also support Treg expansion and maintenance (29) . Indeed, the role of IL-2 in Treg homeostasis has recently been re-evaluated (31, 32) with evidence that signaling through the c c , rather than the IL-2R a chain, is crucial for the thymic ontogeny of CD4 + CD25 + Tregs (33). Importantly, IL-2 signaling per se appears to be essential only for the peripheral survival and competitive 'fitness' of Tregs in these models (33, 34) . Experiments performed in vitro have also supported a role for IL-4 and IL-7 in the survival and suppressive activity of murine CD4 +
+ Tregs (19, 20, [35] [36] [37] . Furthermore, both IL-4 and IL-13 induce the differentiation of murine CD4 + CD25 + Foxp3
+
Tregs from CD4
+ CD25 À precursors (38). As a preliminary step toward the optimization of expansion protocols for clinical practice, we have examined the effect of IL-2 on human CD4 + CD25 + Tregs. We have established that this cytokine maintains the regulatory phenotype in vitro, preserving maximal suppressive potency and increasing the expression of FOXP3 and CD25, cytotoxic T lymphocyte antigen-4 (CTLA-4) (CD152) and glucocorticoid-induced tumor necrosis factor receptor superfamily member number 18 (GITR). IL-2 also prevents the apoptosis of Tregs, though this did not appear to be an important mechanism underlying the preservation of maximal regulatory function, which required the presence of an intact PI3K-signaling pathway. The individual c c cytokines IL-4, IL-7 and IL-15 were also able to maintain maximal regulatory function, suggesting a degree of redundancy of the cytokines required to maintain Treg function in vitro that may recapitulate the key role of the c c in the thymic ontogeny of these cells.
Methods
Source of cells
Human CD4
+ T cells were purified from either buffy coat preparations (Blood Transfusion Service, London, UK) or blood, immediately following venesection of healthy volunteers.
Culture medium and cytokines
Human CD4
+ T cells were cultured in Rosswell Park Memorial Institute 1640 medium, supplemented with penicillin (100 IU ml À1 ), streptomycin (100 mg ml À1 ) and L-glutamine (2 mM) (RPMI-PSG; all from GIBCO, Paisley, UK) and 10% v/v human AB serum (HS; Biowest, Ringmer, UK). Recombinant human IL-2 (Roche, Lewes, UK), IL-4 (Biosource, Nivelles, Belgium), IL-7 (R&D Systems, Abingdon, UK) and IL-15 (Peprotech, Northampton, UK) were used at the concentrations indicated in figure legends.
Purification of T cell subsets
Human PBMCs were isolated from blood samples by density gradient centrifugation over Lymphoprep TM (Axis-Shield, Oslo, Norway). Washed PBMCs were re-suspended in ice-cold RPMI-PSG supplemented with 2% v/v HS, before gentle rolling at 4°C for 25 min with murine mAbs against CD8 (B-H7), CD14 (B-A8), CD16 (B-E16) (all from Diaclone, Boldon, UK), CD19 (HD37), CD56 (MEM188), glycophorin A (BRIC 256) (all from Chemicon, Chandlers Ford, UK), CD33 (P67.6) and TCR cd (11F2) [both from Becton Dickinson (BD), Cowley, UK]. After washing, antibody-coated PBMCs were incubated with goat anti-mouse Fc-coated Biomag â beads (Qiagen; Metachem Diagnostics, Northampton, UK) for 25 min and non-CD4 + T cells depleted by magnetic separation. Isolated CD4 + T cells were washed and then mixed with 500 ll anti-CD25-coated beads (Dynal, Wirral, UK) by gentle rolling at 4°C for 20 min. CD25-depleted cells (referred to as CD25 À ) were removed in the supernatant and the beads were washed four times by gentle pipetting in RPMI-PSG/2% v/v HS. After washing, the beads were re-suspended in RPMI-PSG/10% v/ v HS with DETACHabead â (Dynal) and shaken at room temperature for 45 min to release CD25 + T cells; the beads were removed by magnetic separation, leaving CD25 + cells in the supernatant. Purity ranged from 92 to 98% for CD25-depleted CD4 + T cells and 90 to 97% for CD4 + CD25 + T cells. The number of CD4 + CD25 + T cells isolated was typically 1-3% of total CD4 + cells.
Pre-incubation with cytokines
Isolated human CD4 + T cells were suspended at a density of 5 3 10 5 -1 3 10 6 cells ml À1 in RPMI-PSG/10% v/v HS, before aliquoting volumes of 400 ll into 48-well plates. Cytokines were added at the concentrations indicated and the volumes made up to 500 ll. LY294002 (LY), a chemical inhibitor of PI3K (Calbiochem; Merck, Beeston, UK), was used at 10 lM and ciclosporin A (CSA) (Sigma, Poole, UK) at 0.5 lM during pre-incubations. Where cells were pre-incubated with cytokines and either of the drugs, the appropriate volumes of the diluents dimethylsulfoxide (for LY: Sigma) and ethanol (for CSA: VWR, Lutterworth, UK) were added to the medium or cytokine controls. After overnight incubation (18 h), cells were washed three times in RPMI-PSG before use in proliferation assays or surface phenotyping.
Proliferation assays
T cell proliferation assays were set-up in triplicate in 96-well, round-bottomed plates, suspending both CD25 À and CD25 + CD4 + T cells in RPMI-PSG with 10% v/v HS at 1 3 10 5 cells ml À1 , from which serial dilutions were prepared. The T cells were added to the plate in 50 ll aliquots (5 3 10 3 T cells per well) in the combinations described in the figures. Anti-CD3/anti-CD28-coated beads (Dynal) were added at 1000 beads per well and the final volume in each well adjusted to 250 ll. On day 5, the plate was pulsed with 1 lCi of [ 3 H]-labeled thymidine per well (Amersham Biosciences, Chalfont St Giles, UK). Preliminary experiments revealed that proportional suppression of proliferation increased with time in this assay system, independently of the prior IL-2 history of the CD4 +
CD25
+ T cells; identical conclusions were derived when shorter cultures were examined, though proportional suppression was lower, hence our choice of 5 days. After 16-20 h, cells were harvested in routine fashion for liquid scintillation counting. The percentage suppression was determined using the formula {1 À [counts per minute (c.p.m.) CD25
À/+ / c.p.m. CD25
À alone]} 3 100.
Flow cytometry
T cell subsets were stained with anti-CD4-allophycocyanin (APC) (S3.5), CD25-PE (CD25-3G10) (both from Caltag Medsystems Ltd, Towcester, UK) and CD3-FITC (UCHT-1) (Sigma washing and then re-suspending in 100 ll Annexin-binding buffer (BD PharMingen). Cells were stained with Annexin V (conjugated to PE for bead-separated populations and APC for flow-sorted CD25 subsets) and 7-aminoactinomycin-D (7-AAD) (BD PharMingen) at room temperature. A volume of 20 ll of Perfect-Count â microspheres (Cytognos, Santander, Spain) was added by reverse pipetting, before re-suspension in a total volume of 250 ll binding buffer. Acquisition was limited by gating on Perfect-Count â microspheres, collecting 2500 events for each sample. Viable cell number was determined by counting Annexin V-FITC/7-AAD doublenegative events in a lymphocyte gate. Relative cell viability was determined using the formula: (viable cell number acquired under condition 'x')/(viable cell number acquired after incubation in medium alone).
Western blots
Isolated CD4
+ T cells were suspended (1 3 10 6 cells ml
À1
) in RPMI-PSG/10% v/v HS, before being dispensed into 48-well plates. During pre-incubations, IL-2 was used at 0.5 ng ml
and LY at 10 lM in a final volume of 500 ll. After overnight incubation (18 h), cells were washed three times in phosphatebuffered saline (PBS) (Oxoid, Hampshire, UK). The cells were treated with ice-cold lysis buffer containing 1% (v/v) Triton-X 100, 1 mM Na 3 VO 4 , 1 mM EDTA and a protease inhibitor cocktail (Sigma) for 30 minutes. The lysate was cleared by centrifugation at 13 000 3 g for 20 minutes at 4°C, before measurement of protein concentration with the Bio-Rad Protein Quantitation Kit TM (Bio-Rad Laboratories, Hemel Hempstead, UK). Cell lysate (10 lg of protein) was then separated by 10% w/v SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. Membranes were blocked for 1 h with 5% w/v skimmed milk in PBS with 0.01% v/v. Tween 20, before probing with the anti-phospho-serine/threonine kinase (pAKT) antibody (193H12) (Cell Signaling Technology, Beverly, MA, USA). Bound antibody was revealed with HRPconjugated anti-rabbit antibody, using enhanced chemiluminescence (Amersham Biosciences). The intensity of bands was determined with the GelDoc-It Imaging System â using LabWorks software (UVP Ltd, Cambridge, UK).
Statistical analysis
Statistical analyses were performed using GraphPad TM Prism, version 4.00 for Windows TM (GraphPad TM Software, San Diego, USA). Paired t-tests were applied for two columns of data; one-way analysis of variances with Tukey's adjustment for multiple comparisons were applied for three or more columns. (Fig. 1A) . Maximal enhancement was usually observed at 0.5 ng ml
Results
Incubation
À1
: using this concentration, the mean enhancement of suppression in 1:1 co-cultures in 15 experiments was 15.4% (P < 0.0001; These results suggested that pre-incubation in IL-2 either enhanced the suppressive potency of human CD4 + CD25 + Tregs or prevented deterioration in potency that occurred with overnight incubation in medium alone. To determine whether enhancement or maintenance of maximal suppressive potency was predominant, we isolated CD4 + CD25 + T cells on consecutive days from single donors. We compared the suppression observed in an assay when first isolated (day 0) with that seen after overnight incubation in medium, in medium with IL-2 (0.5 ng ml
) and with freshly isolated CD4 + CD25 + T cells from the same donor. Serial comparisons of cells from individual donors controlled for differences in purity between selections-though these were likely to be small, since all separations were 90-98% CD4 + CD25 + . Pre-incubation with IL-2 did not enhance suppression beyond that seen either with freshly isolated cells or cells used in proliferation assays on day 0 (Fig. 1C) . Cells incubated in medium alone were less suppressive, suggesting that IL-2 acted to maintain, rather than to enhance, optimal suppressive potency.
IL-2 is a survival factor for CD4 + CD25 + Tregs, but prevention of apoptosis is not sufficient to maintain maximal suppression A trivial explanation for our results was that IL-2 simply acted as a survival factor for Tregs (18). Although equal numbers of viable cells were used in each proliferation assay, we sought to rule out an anti-apoptotic effect as an explanation for the observed phenomenon by comparing the ability of IL-2 to maintain CD4 + CD25 + T function with another pro-survival cytokine, IL-6. Isolated CD4 + CD25 + T cells were incubated overnight with medium or medium containing IL-2 (0.5 ng ml
) or IL-6 (50 ng ml À1 ). Viable cells were counted using a bead-based flow cytometric method and Annexin V/ 7-AAD staining to exclude dead cells or those undergoing apoptosis. In a similar manner to IL-2, IL-6 was able to reduce CD4 +
CD25
+ T cell apoptosis, with a mean increase in survival of 19 versus 21% for IL-2 ( Fig. 2A) . Despite protecting from apoptosis, IL-6 had no effect on the suppressive potency of the CD4 + CD25 + T cells ( Fig. 2B and C). We next determined whether the pro-survival effect of IL-2 could be dissociated from the ability to maintain maximal suppression. IL-2 is thought to prevent apoptosis through the PI3K-dependent activation of protein kinase B/serine/threonine kinase (AKT) (41). However, work with murine CD4 + CD25
+
Tregs and human CD4 + CD25 + Treg lines has shown that inhibition of PI3K with LY does not abolish IL-2 pro-survival effects in these cells (42, 43). IL-2R signaling is incompletely understood and effects such as cell-cycle progression and increased survival are thought to occur through integration of distinct downstream pathways (24). We surmised that inhibition of PI3K, although unlikely to inhibit pro-survival effects, 
CD25
+ T cells at a 1:1 ratio with CD4 + CD25 À T cells and the augmentation achieved by pre-incubating with IL-2 varied between individuals. IL-2 pre-incubation (0.5 ng ml 
+ T cells were selected from fresh blood. Some of them were used in a suppression assay (day 0), while the remainder were incubated overnight with medium or medium and IL-2 (0.5 ng ml may interfere with the maintenance of maximal suppression by IL-2. We first sought to demonstrate that IL-2 activates PI3K within human CD4 + CD25 + T cells, before showing that LY is able to inhibit this rise in activity. Overnight incubation with IL-2 increased AKT activation in CD4 + CD25 + T cells, and this phenomenon could be inhibited by co-incubation with LY (Fig. 3) . We next examined the functional consequences of LY during pre-incubation of the CD4 + CD25 + T cells, before testing their suppressive potency within our assay system. While LY did not inhibit IL-2 pro-survival effects (mean increase in survival of 19% IL-2 versus 23% IL-2 + LY, P > 0.05; Fig. 4A ), it nevertheless abolished the maintenance of maximal suppression ( Fig. 4B and C) . In contrast, LY pre-incubation had no effect on suppression mediated by cells incubated in medium alone (Fig. 4C) .
Maintenance of maximal CD4
+ CD25 + Treg suppression by IL-2 is not dependent on simultaneous TCR signaling A possible explanation for the maintenance of suppression with pre-incubation of CD4 + CD25 + T cells with IL-2 was the receipt of signals delivered by the TCR, by virtue of interactions with MHC class II expressed by other CD4 + CD25 + T cells. Exogenous IL-2 combined with TCR signaling is known to enhance suppression (19); furthermore, CD4 + CD25 + Tregs may respond to epitopes derived from self-TCRs (44). IL-2 had a variable effect on MHC class II expression by CD4 + CD25 + T cells: in some experiments, a small increase in the percentage of cells expressing HLA-DR was observed, though this was not a consistent finding (Fig. 5A ). To prevent TCR signaling, we added CSA during pre-incubation with IL-2 or medium alone, thereby inhibiting calcineurin and Jun N-terminal kinase/p38 activation and proliferation without influencing IL-2 signaling (45, 46). At a concentration that yielded 90% inhibition of T cell proliferation when added during stimulation with Dynabeads â coated with antibodies against CD3 and CD28
(data not shown), CSA had no effect on the ability of IL-2 to maintain maximal suppressive potency (Fig. 5B ).
IL-2 increases the expression of CD4 + CD25 + Treg markers
We had not expected to see functional changes in CD4
Tregs at such low concentrations of IL-2, since these cells do not proliferate in response to IL-2 without concomitant TCR (47) or GITR stimulation (40) and constitutively express several proteins involved in down-regulation of cytokine signaling (39, 40, 48). To examine further the effect of IL-2 on the phenotype of human CD4 + CD25 + Tregs, we assessed the expression of CD25, which is up-regulated by IL-2 via STAT5 (49, 50). IL-2 increased CD25 expression at concentrations as low as 0.05 ng ml À1 (data not shown); this effect appeared to be maximal at 0.5 ng ml À1 (Fig. 6A) , with no higher expression 
CD25
+ T cells were immunomagnetically selected, before overnight (18 h) incubation in complete medium with or without IL-2 (0.5 ng ml
À1
). The PI3K inhibitor LY (10 lM) was included in some of the wells containing IL-2. Cell lysates (10 lg protein per lane) were prepared in routine fashion for Western blotting, before probing the membranes with anti-pAKT (clone 193H12). Bands were visualized with HRP-conjugated anti-rabbit antibody, using enhanced chemiluminescence. The ratios of the intensities (total OD/area) of the pAKT to b-actin bands are noted. A representative of two independent experiments is shown. observed at 5 ng ml À1 (data not shown). We also examined CTLA-4 (CD152) and GITR, two other distinctive markers of CD4 + CD25 + Tregs (40, 51-53). IL-2 up-regulated intracellular CTLA-4 expression by CD4 + CD25 + T cells at 0.5 ng ml À1 (Fig. 6B) . Overnight incubation induced CD25 and CTLA-4 expression to higher levels than those seen in freshly isolated cells ( Fig. 6A and B) . Neither up-regulation of CD25 nor CTLA-4 was inhibited by LY ( Fig. 6A ; data for CTLA-4 not shown), suggesting that either the up-regulation of these molecules and the maintenance of maximal suppressive potency were unrelated phenomena or up-regulation was necessary but not sufficient to maintain optimal suppressor function. Increased CTLA-4 expression by CD4 + CD25 + Tregs after incubation with IL-2 has been noted previously (54). In contrast to murine CD4 + CD25 + Tregs, only 5-10% of freshly isolated CD4 + CD25 + T cells expressed GITR in our hands, using a protocol that yielded >70% cellular expression with activation (data not shown). Pre-incubation with IL-2 increased the percentage of CD4 + CD25 + T cells expressing GITR, but the effect was marginal (Fig. 6C) . In all cases, we assumed that differences in expression reflected increases in protein expression per unit cell volume rather than increases in the size of the CD4 + CD25 + Tregs (Fig. 6D) . We considered that the bead-selected CD4 + CD25 + T cells were likely to represent a heterogeneous population, comprising both CD45RA
+ and CD45RO + regulatory and conventional T cells. Human Tregs of both naive and memory phenotypes have been characterized (55, 56), either of which could have contributed to the phenomenon observed in the current study. Thus, one explanation for the maintenance of optimal suppressive potency by IL-2 was the selective survival of a more potent regulatory sub-population in our overnight culturesone study, for example, suggests that memory Tregs are more potent suppressors than their naive CD4 + CD25 + counterparts (55). However, the composition of the CD4 + CD25 + T cell population, as documented by CD45RA/RO staining, remained unchanged with overnight culture in medium containing IL-2 (Fig. 6E) , suggesting that gross changes in the Treg sub-populations were unlikely to be responsible for the maintenance of optimal suppressive potency. Nevertheless, a more subtle selective effect of IL-2 on one or other of the Treg sub-populations, operating at the level of their suppressor effector function, could not be excluded. ). Proliferation assays were set-up as in Fig. 2 . A representative experiment is shown, of three performed with different donors. Error bars represent standard deviations. ns P >0.05, **P < 0.01 (analysis of variance). ); forward scatter was assessed by flow cytometry. (E) IL-2 has no effect on CD4 +
CD25
+ T cell expression of CD45RA/RO with overnight culture, suggesting that gross changes in the naive and memory Treg sub-populations are unlikely to be responsible for the maintenance of optimal suppressive potency. + preparations (Fig. 1B) . Although the majority of CD4 + CD25 INT T cells do not express the IL-2R b chain (CD122) and thus lack a functional high-affinity IL-2R, the possibility remained that they were the specific target of IL-2 in our experiments: IL-2 may have conferred a regulatory phenotype on the CD25
IL-2 pre-incubation influences only the CD4 + CD25 HI T cells
INT T cells, thereby increasing the regulatory population in the CD4 + CD25 + fraction. To exclude this possibility, we used FACS TM to separate the CD25 HI and CD25 INT populations, pre-incubating these cells separately with IL-2. IL-2 had no effect on the ability of the CD25
INT population to suppress, but augmented suppression by the CD25 HI T cells (Fig. 7A ). As would be expected, IL-2 had no effect on the apoptosis of the CD25
INT population (Fig. 7B) . A small sub-population of CD25
INT T cells upregulated CD25 expression in response to IL-2 (Fig. 7C) , thought likely to represent the minority expressing CD122, but there was no change in the overall population; in contrast, the CD25 HI T cells almost universally up-regulated CD25 (Fig. 7D) . However, the expression of other phenotypic markers, such as CD45RA and CD45RO, was not appreciably altered by overnight exposure to IL-2, confirming the specificity of the CD25 response (Fig. 7E) . Furthermore, the expression of CD127-the IL-7R a chain expressed at low levels by CD4 + CD25 HI T cells (60, 61)-showed no significant change with overnight exposure to IL-2, but could be abolished with exposure to IL-7, attributed to activation and internalization of the IL-7R (62) (Fig. 7F) .
Pre-incubation with IL-4, IL-7 or IL-15 maintains maximal suppressive potency of CD4 + CD25 + T cells
Expansion and maintenance of CD4
+ CD25 + Tregs in vitro necessarily involves withdrawal from many factors present in vivo, coupled with repetitive high-affinity stimulation. Under these circumstances, IL-2 alone may not be an ideal maintenance cytokine, since pre-incubation with IL-2 can prime for cell death on re-stimulation (63) and other c c cytokines may have properties that could support optimal expansion (64) . Indeed, there is evidence supporting a degree of redundancy in the ability of c c cytokines to maintain functional CD4 + CD25 + Treg populations (6, 19, (35) (36) (37) 65) . We hypothesized that these other c c cytokines would maintain human CD4 +
CD25
+ Treg function and phenotype in a manner similar to IL-2. Preincubation with IL-4, IL-7 or IL-15 maintained maximal suppression by human CD4 + CD25 + Tregs, though the concentrations required were 20-to 50-fold higher than for IL-2 (Fig. 8A) , thought to reflect the high density of expression of the IL-2 abc receptor by CD4 +
+ Tregs. The c c cytokines that also activate STAT5 (IL-7 and IL-15) increased CD25 and CTLA-4 expression to levels similar to those seen with IL-2, whereas IL-4 had no effect on the expression of these markers (Fig. 8B) . As with IL-2, IL-7 and IL-15 had only a small impact on the expression of GITR, in contrast to IL-4, which made no difference. The resistance of IL-2-induced up-regulation of CTLA-4 to PI3K inhibition and the ability of other cytokines activating STAT5 to increase levels of this marker together suggested that CTLA-4 expression by CD4 + CD25 + Tregs may be regulated through STAT5.
Pre-incubation of human CD4 + CD25 + T cells with IL-2, IL-7 or IL-15, but not IL-4, up-regulates the expression of FOXP3
Transfection of human CD4
+ CD25 À T cells with FOXP3 confers a hypoproliferative, suppressive phenotype on them and induces the expression of CD25 and CTLA-4 (66)-key features of CD4 + CD25 + Tregs. We speculated that the c c cytokines may act 'upstream' of FOXP3, functioning to maintain tonic expression of this gene and therefore the regulatory phenotype. While pre-incubation of CD4 + CD25 + T cells with IL-2, IL-7 or IL-15 increased the expression of FOXP3 beyond that observed in either freshly isolated T cells or those incubated in medium alone, IL-4 had no impact on its expression (Fig. 9A) ; furthermore, up-regulation of FOXP3 by IL-2 could not be inhibited with LY at concentrations that abolished the maintenance of maximal suppressive potency (Fig. 9A ).
FOXP3 expression of CD4
+ CD25 À T cells remained unaltered, regardless of the cytokine examined (Fig. 9B) .
Discussion
The manipulation of human CD4 + CD25 + Tregs in vitro is a pivotal first step toward their therapeutic application in autoimmune disease and transplantation. A thorough understanding of the conditions required to maintain CD4 + CD25
+
Tregs in vitro is required. To our knowledge, this is the first study to demonstrate the role of IL-2 in the maintenance of the regulatory phenotype of human CD4 + CD25 + T cells, a phenomenon that appeared to be dependent upon the integrity of the PI3K/AKT-signaling pathway. Key advances offered by the current work that merit special emphasis include our examination of human, rather than murine, CD4 + CD25 + T cells and the demonstration of a phenomenon that occurred in the absence of attendant TCR signals. As recently reviewed, there are key differences between the murine and human immune systems (67) . Advancement of immunological knowledge of relevance to medicine will only ultimately come from the study of human T cells: murine studies, while interesting and vital, are insufficient alone to recommend novel immunotherapeutic strategies, since therapies that seem to work in the mouse may either fail to be effective or even prove detrimental in higher mammals [e.g. anti-CD28 and anti-CD154 in transplantation tolerance (68) ]. IL-2 maintained maximal suppressive potency and prevented apoptosis, while up-regulating the expression of key cellular markers. These effects occurred uniquely in the regulatory CD4
+ CD25 HI population and were not observed in the non-regulatory CD4 + CD25 INT cells, likely to be due to their well-recognized differential expression of CD122. Using our in vitro system, we also demonstrated a redundancy of IL-2 with other c c cytokines-IL-4, IL-7 and IL-15-which ), the cells were washed and proliferation assays setup as before, except that the CD25 HI subset were co-cultured with the CD25 À cells at a 1:2 ratio. A representative of two independent experiments is shown. Error bars represent standard deviations. ns P > 0.05, *P < 0.05 (analysis of variance). (B) IL-2 reduces apoptosis of the CD25 HI subset, but has no effect on the CD25
INT . After overnight incubation, viable cell recovery was assessed as in Fig. 2 . Error bars represent standard deviations of triplicate wells. ns P > 0.05, *P < 0.05 (Student's t-test). similarly maintained optimal suppressive potency. Whether these cytokines may show additive or even synergistic effects in vitro was not investigated in the current study, but could be explored in future, pre-clinical work designed to optimize culture conditions for the maintenance and expansion of human Tregs.
Pre-incubation of human CD4 + CD25 + T cells with IL-2 initially appeared to enhance their suppressive properties in vitro. IL-2 activates the suppressor effector function of murine Tregs in vitro: the initial production of IL-2 by CD25
À responder cells is essential to allow the ultimate suppression of CD25 À IL-2 mRNA (20). IL-2 production by responder CD25
À cells is thought to promote CD25 expression by CD4 + CD25 + Tregs, which facilitates Treg uptake and sequestration of IL-2 (21, 22, 69) and the expression of forkhead box protein 3, murine nomenclature (Foxp3) (70) . We hypothesized that incubation with IL-2 may 'pre-activate' these regulatory pathways, thus augmenting suppression.
However, comparing pre-incubated with freshly isolated cells provided no evidence for the enhancement of suppression with IL-2, but supported a model in which IL-2 protects the cells from deteriorating suppressor function in the presence of medium alone. This led us to determine whether the role of IL-2 was simply the inhibition of apoptosis within the bulk population or the provision of unique signals that maintain suppressive potency of individual cells. We and others (18) have found that IL-2 reduces the rapid decline in viability of freshly isolated human CD4 + CD25 + T cells in vitro (20-30% apoptosis in 20 h; data not shown). However, this survival effect was unlikely to be of importance to the current phenomenon, since IL-6 had no effect on suppression despite reducing apoptosis, while blockade of PI3K with LY had no effect on viability despite inhibiting suppression. Previous work has shown that pre-incubation with IL-2 enhances the suppressive function of murine CD4 +
CD25
+ Tregs if they are also stimulated through the TCR (19). Importantly, however, the effect we observed did not depend on TCR signalingas may occur by T to T cell presentation of self-peptidessince it could not be inhibited with CSA. Taken together, our data favored a model in which cytokine signaling maintains the regulatory phenotype in a primed state beyond antiapoptotic or suppression-activating effects. 
+ T cells, in contrast to IL-4, which has no impact on its expression. Despite abolishing the maintenance of optimal suppressive potency by IL-2, the PI3K inhibitor LY has no effect on the increased expression of FOXP3 induced by this cytokine (IL-2 and IL-2 + LY responses are superimposable). (B) In contrast to the CD25 + T cells, FOXP3 expression by the CD25 À CD4 + T cells is not influenced by c c cytokines.
All our initial studies used immunomagnetically selected CD4 + CD25 + T cells, which are known to contain a significant population of non-regulatory CD4 + CD25 INT cells that confound the interpretation of functional assays. Furthermore, the CD4 + CD25 + Treg population itself is known to be heterogeneous, comprising both naive and memory sub-populations (55, 56). However, while FACS TM allows the selection of Tregs to high stringency, it suffers the practical limitation of yielding far fewer cells to work with-<50% of the number selected using beads-precluding the parallel examination of multiple culture conditions. In addition, prolonged sorting times for large numbers of cells from buffy coats also reduced the viability of the recovered cells prior to pre-incubation with the cytokines. In contrast, beads yielded a functional population that was more rapidly selected and that displayed the expected properties of Tregs, albeit less potently. Moreover, studies examining the expression of CD45RA and CD45RO by the CD4
+ T cells demonstrated that the observed phenomenon could not be explained simply by a survival advantage of memory Tregs, which are thought to mediate more potent suppression in vitro (55). The recent development of FACS TM protocols involving the marker CD127 are a welcome addition to the field, facilitating human Treg studies by allowing a greater number of viable cells to be sorted in one sitting (71, 72) . While the utility of this marker had not been recognized at the time our initial experiments were performed, we were nevertheless able to show in more recent experiments that IL-2 appeared not to modulate the pattern of its expression with overnight culture; in contrast, IL-7 abolished the expression of CD127, suggesting that it activated and caused internalization of the high-affinity IL-7R in these cells (62) . However, the possibility of a CD127-independent effect of IL-7 on the CD4
À Tregs could not be excluded.
The mechanism underlying the 'protective' influence of IL-2 and the other c c cytokines on human CD4
+ CD25 + T cell function currently remains unclear. Changes in expression of CD25 and CTLA-4 did not correlate with functional potency in our system, although both have been implicated in the function of Tregs in vitro. Thus, high expression of CD25-up-regulated by the early release of IL-2 from responder cells-is thought to allow CD4 + CD25 + Tregs to compete with effector T cells for this growth factor (21, 22). Though controversial (19), CTLA-4 may also play a role in suppression in vitro (73) . However, up-regulation of these markers was thought to be of questionable importance in our system for three reasons. First, IL-2 increased the expression of CD25 and CTLA-4 to levels beyond those observed in freshly isolated CD4 + CD25 + T cells, yet did not truly enhance suppression. Second, the inhibition of PI3K with LY during pre-incubation with IL-2 prevented the maintenance of maximal suppression, yet had no effect on upregulation of either molecule. Finally, IL-4 failed to up-regulate either marker on human CD4 + CD25 + T cells, yet was effective in maintaining optimal suppression. We suggest two potential scenarios: either other unrecognized mechanisms underlie optimal maintenance of the suppressive phenotype in vitro or-in the case of IL-2, IL-7 and IL-15-the up-regulation of these molecules is necessary but not sufficient for the maintenance of Treg function.
Interestingly, the expression patterns of FOXP3 mirrored those of CD25, CTLA-4 and GITR: up-regulation was observed with all cytokines except IL-4. This pattern of parallel expression was consistent with the known up-regulation of Treg phenotypic markers by murine Foxp3 (74) and human FOXP3 (75), taken as evidence that FOXP3 may act as a transcriptional activator-rather than a repressor-in certain contexts. The apparent decoupling of the suppressive potency of CD4 + CD25 + T cells from increments in FOXP3 expression observed in the current study is reminiscent of work performed by Allan et al. (75) , which suggests that additional factors beyond FOXP3 are required to confer full regulatory function on human CD4 + T cells. Such additional factors, which currently remain uncharacterized, may be the specific target of the c c cytokines and presumably involve PI3K signaling in this context. Though controversial, these authors suggest that FOXP3 may be viewed as an activation marker in human CD4 + T cells, necessary but not sufficient for the induction of regulatory activity (75 (Fig. 9B) or other Treg markers (data not shown), suggesting that the increased expression by CD4 + CD25 + T cells represented a genuine, differential effect of the c c cytokines, rather than background TCR activation. Interestingly, a recent study by Zorn et al. (78) concurs with our own data, demonstrating that IL-2 selectively up-regulates the expression of FOXP3 by CD25 + -but not CD25
À -CD4
+ T cells through a STAT-dependent mechanism. Furthermore, the clinical relevance of this phenomenon was highlighted by the expansion of CD4 + CD25 + T cells in vivo by low-dose IL-2 treatment in patients with metastatic neoplasia and chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation. The upstream pathways of FOXP3 remain unclear (79) , but-at least for IL-2-appear not to depend on PI3K-signaling mechanisms (Fig. 9A) . Future work will need to dissect the PI3K-independent intracellular pathways mediating the transcription of FOXP3 by some, but not all, of the c c cytokines, and how they might differ between individual family members.
Recent work by Bensinger et al. (42) has demonstrated constitutive inhibition of early signaling downstream of IL-2-activated PI3K by phosphatase and tensin homolog deleted on chromosome 10 (PTEN) in murine CD4 + CD25 + Tregs, confirmed in a subsequent study by Walsh et al. (80) . This observation seems at odds with the results of the current study, which suggest that IL-2 and other cytokines preserve optimal Treg function by a PI3K-dependent mechanism. There are three possible explanations for this apparent disparity. First, the PI3K-dependent pathway responsible for the maintenance of optimal CD4
+ CD25 + Treg suppression may be less efficiently inhibited by PTEN than the PDK/AKT pathway examined by Bensinger and others (81) . Second, the possibility remains of a late PI3K-dependent mechanism, which escapes the immediate PTEN inhibitory activity described by these authors (42). Indeed, there are examples of such delayed PI3K activation in T cells, including the STAT-5-dependent activation of PI3K/AKT required for IL-2-induced cyclin D2 expression and cell-cycle progression (82, 83) . Furthermore, our Western blots confirmed the presence of pAKT in T cells that were incubated with IL-2 overnight, providing direct evidence for late activation of PI3K in these cells. Finally, the role of PI3K in murine and human CD4
+ CD25 + T cells may show fundamental differences unrelated to pathway specificity or kinetics of activation. Indeed, a recent study provides some evidence for this third hypothesis, showing that downstream signals mediated by the altered activation of AKT were actually required for the suppressive function of human CD4 +
CD25
+ Tregs (84); changes in the activity of PI3K or the basal expression of src homology 2-containing inositol phosphatase or PTEN, which could have accounted for the altered activation status of AKT, were not observed. Taken together, we suggest that these data and our own support a mechanism of delayed, or sustained, activation of PI3K in human CD4
+ CD25 + T cells by c c cytokines, possibly involving STAT5-though other STAT proteins are presumably also implicated, since STAT6 is known to mediate IL-4 signaling in T cells (24). Further work is required to explore both the role of STAT5 in the IL-2-induced preservation of human Treg viability versus potency, and the kinetics of its activation by the c c cytokines in these cells.
In summary, we have demonstrated for the first time that the c c cytokines IL-2, IL-4, IL-7 and IL-15 maintain optimal suppressive function by human CD4 + CD25 HI Tregs. While the mechanism of this phenomenon remains to be fully defined, it is at least in part dependent upon the activation of PI3K. We propose that this redundancy of the stimuli governing suppressive function provides a mechanism to ensure maximal flexibility of regulation in various different microenvironments in vivo, where one or more c c cytokines may predominate. Our data suggest that the use of c c cytokines in protocols to culture CD4 + CD25 HI Tregs in vitro may optimize expansion while maintaining maximal suppressive potency. Future work will dissect the mechanisms underlying this 'priming' phenomenon, thus offering the potential to augment human CD4
+ CD25 HI Treg function in vivo by the manipulation of key effector pathways.
